Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMKZVLH)

Drug Name
Lefradafiban Drug Info
Synonyms BIBU-104; BIBU-104XX; BIBV-104
Indication
Disease Entry ICD 11 Status REF
Angina pectoris BA40 Phase 1 [1]
Cross-matching ID
PubChem CID
9576916
ChEBI ID
CHEBI:60634
CAS Number
CAS 149503-79-7
TTD Drug ID
DMKZVLH

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) TT38RM1 ITA2B_HUMAN; ITB3_HUMAN Modulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DTT ITGA2B 2.186 1.202 1.585 2.7
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Angina pectoris
ICD Disease Classification BA40
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DTT ITGA2B; ITGB3 7.83E-01 -0.11 -0.45
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02264106) Influence of Pantoprazole on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of Lefradafiban Over 5 Days in Healthy Subjects. U.S. National Institutes ofHealth.
2 Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty. Heart. 2001 Apr;85(4):444-50.